Discontinuation of anti-arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation

Koichi Inoue, Toshiya Kurotobi, Hiroshi Itoh, Ryusuke Kimura, Yuko Toyoshima, Norihisa Itoh, Yoshiharu Higuchi, Motoo Date, Yasushi Koyama, Katsuomi Iwakura, Kenshi Fujii

Research output: Contribution to journalArticle

Abstract

Background: Anti-arrhythmic drugs (AADs) are often administered following catheter ablation (CA) for persistent atrial fibrillation (peAF) to maintain sinus rhythm (SR). It remains unclear whether AADs can be withdrawn in patients showing no recurrence after CA. Method: We administered hybrid therapy consisting of CA and AAD (bepridil) in 75 patients with peAF. Withdrawal of AADs was attempted in patients who had no recurrence of AF for ≥6 months. We followed them for 22716 months. Results: Patients received 1.270.4 sessions of CA and a mean bepridil dose of 131746 mg/day. After a 3-month "blanking period", 62 (83%) patients maintained SR without recurrence of tachyarrhythmia for ≥6 months. AADs were discontinued in 41 patients who agreed to medication withdrawal. Ten of these (24%) experienced a relapse of tachycardia, and these patients had a higher incidence of residual inducibility of tachyarrhythmia at the end of the CA procedure (70% vs. 32%; P=0.03) and required a higher dose of bepridil to maintain SR (170748 mg vs. 106730 mg; P

Original languageEnglish
Pages (from-to)170-174
Number of pages5
JournalJournal of Arrhythmia
Volume28
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Bepridil
Catheter Ablation
Anti-Arrhythmia Agents
Atrial Fibrillation
Pharmaceutical Preparations
Tachycardia
Recurrence
Therapeutics
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Discontinuation of anti-arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation. / Inoue, Koichi; Kurotobi, Toshiya; Itoh, Hiroshi; Kimura, Ryusuke; Toyoshima, Yuko; Itoh, Norihisa; Higuchi, Yoshiharu; Date, Motoo; Koyama, Yasushi; Iwakura, Katsuomi; Fujii, Kenshi.

In: Journal of Arrhythmia, Vol. 28, No. 3, 06.2012, p. 170-174.

Research output: Contribution to journalArticle

Inoue, K, Kurotobi, T, Itoh, H, Kimura, R, Toyoshima, Y, Itoh, N, Higuchi, Y, Date, M, Koyama, Y, Iwakura, K & Fujii, K 2012, 'Discontinuation of anti-arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation', Journal of Arrhythmia, vol. 28, no. 3, pp. 170-174. https://doi.org/10.1016/j.joa.2011.12.005
Inoue, Koichi ; Kurotobi, Toshiya ; Itoh, Hiroshi ; Kimura, Ryusuke ; Toyoshima, Yuko ; Itoh, Norihisa ; Higuchi, Yoshiharu ; Date, Motoo ; Koyama, Yasushi ; Iwakura, Katsuomi ; Fujii, Kenshi. / Discontinuation of anti-arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation. In: Journal of Arrhythmia. 2012 ; Vol. 28, No. 3. pp. 170-174.
@article{52a780171073462380045da722765205,
title = "Discontinuation of anti-arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation",
abstract = "Background: Anti-arrhythmic drugs (AADs) are often administered following catheter ablation (CA) for persistent atrial fibrillation (peAF) to maintain sinus rhythm (SR). It remains unclear whether AADs can be withdrawn in patients showing no recurrence after CA. Method: We administered hybrid therapy consisting of CA and AAD (bepridil) in 75 patients with peAF. Withdrawal of AADs was attempted in patients who had no recurrence of AF for ≥6 months. We followed them for 22716 months. Results: Patients received 1.270.4 sessions of CA and a mean bepridil dose of 131746 mg/day. After a 3-month {"}blanking period{"}, 62 (83{\%}) patients maintained SR without recurrence of tachyarrhythmia for ≥6 months. AADs were discontinued in 41 patients who agreed to medication withdrawal. Ten of these (24{\%}) experienced a relapse of tachycardia, and these patients had a higher incidence of residual inducibility of tachyarrhythmia at the end of the CA procedure (70{\%} vs. 32{\%}; P=0.03) and required a higher dose of bepridil to maintain SR (170748 mg vs. 106730 mg; P",
author = "Koichi Inoue and Toshiya Kurotobi and Hiroshi Itoh and Ryusuke Kimura and Yuko Toyoshima and Norihisa Itoh and Yoshiharu Higuchi and Motoo Date and Yasushi Koyama and Katsuomi Iwakura and Kenshi Fujii",
year = "2012",
month = "6",
doi = "10.1016/j.joa.2011.12.005",
language = "English",
volume = "28",
pages = "170--174",
journal = "Journal of Arrhythmia",
issn = "1880-4276",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Discontinuation of anti-arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation

AU - Inoue, Koichi

AU - Kurotobi, Toshiya

AU - Itoh, Hiroshi

AU - Kimura, Ryusuke

AU - Toyoshima, Yuko

AU - Itoh, Norihisa

AU - Higuchi, Yoshiharu

AU - Date, Motoo

AU - Koyama, Yasushi

AU - Iwakura, Katsuomi

AU - Fujii, Kenshi

PY - 2012/6

Y1 - 2012/6

N2 - Background: Anti-arrhythmic drugs (AADs) are often administered following catheter ablation (CA) for persistent atrial fibrillation (peAF) to maintain sinus rhythm (SR). It remains unclear whether AADs can be withdrawn in patients showing no recurrence after CA. Method: We administered hybrid therapy consisting of CA and AAD (bepridil) in 75 patients with peAF. Withdrawal of AADs was attempted in patients who had no recurrence of AF for ≥6 months. We followed them for 22716 months. Results: Patients received 1.270.4 sessions of CA and a mean bepridil dose of 131746 mg/day. After a 3-month "blanking period", 62 (83%) patients maintained SR without recurrence of tachyarrhythmia for ≥6 months. AADs were discontinued in 41 patients who agreed to medication withdrawal. Ten of these (24%) experienced a relapse of tachycardia, and these patients had a higher incidence of residual inducibility of tachyarrhythmia at the end of the CA procedure (70% vs. 32%; P=0.03) and required a higher dose of bepridil to maintain SR (170748 mg vs. 106730 mg; P

AB - Background: Anti-arrhythmic drugs (AADs) are often administered following catheter ablation (CA) for persistent atrial fibrillation (peAF) to maintain sinus rhythm (SR). It remains unclear whether AADs can be withdrawn in patients showing no recurrence after CA. Method: We administered hybrid therapy consisting of CA and AAD (bepridil) in 75 patients with peAF. Withdrawal of AADs was attempted in patients who had no recurrence of AF for ≥6 months. We followed them for 22716 months. Results: Patients received 1.270.4 sessions of CA and a mean bepridil dose of 131746 mg/day. After a 3-month "blanking period", 62 (83%) patients maintained SR without recurrence of tachyarrhythmia for ≥6 months. AADs were discontinued in 41 patients who agreed to medication withdrawal. Ten of these (24%) experienced a relapse of tachycardia, and these patients had a higher incidence of residual inducibility of tachyarrhythmia at the end of the CA procedure (70% vs. 32%; P=0.03) and required a higher dose of bepridil to maintain SR (170748 mg vs. 106730 mg; P

UR - http://www.scopus.com/inward/record.url?scp=84870394543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870394543&partnerID=8YFLogxK

U2 - 10.1016/j.joa.2011.12.005

DO - 10.1016/j.joa.2011.12.005

M3 - Article

AN - SCOPUS:84870394543

VL - 28

SP - 170

EP - 174

JO - Journal of Arrhythmia

JF - Journal of Arrhythmia

SN - 1880-4276

IS - 3

ER -